Evidence map›Paper›PMID 38746162›Full record

ArticleResearch square2024

A feasibility study of [18F]F-AraG positron emission tomography (PET) for cardiac imaging - myocardial viability in ischemia-reperfusion injury model.

Uttam Shrestha, Hee-Don Chae, Qizhi Fang, Randall J Lee, Juliet Packiasamy, Lyna Huynh, Joseph Blecha, Tony L Huynh, Henry F VanBrocklin, Jelena Levi and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Uttam ShresthaUniversity of California San Francisco.
Hee-Don ChaeUCSF: University of California San Francisco.
Qizhi FangUniversity of California San Francisco.
Randall J LeeUCSF Medical Center.
Juliet PackiasamyUCSF: University of California San Francisco.
Lyna HuynhUCSF: University of California San Francisco.
Joseph BlechaUCSF: University of California San Francisco.
Tony L HuynhUCSF: University of California San Francisco.
Henry F VanBrocklinUCSF: University of California San Francisco.
Jelena LeviUCSF: University of California San Francisco.
Youngho SeoUCSF: University of California San Francisco.

Funding

[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapyR01HL160688 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jelena Levi, Youngho Seo · 2022 to 2026
$3.4M
MicroPET/CT for Small Animal ImagingS10RR023051 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VANBROCKLIN, HENRY F. · 2007 to 2007
$1.3M
High-throughput microPET/CT at UCSF Preclinical Imaging CoreS10OD034286 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEO, YOUNGHO · 2023 to 2023
$662k
NCRR NIH HHS S10 RR023051NHLBI NIH HHS R01 HL160688NIH HHS S10 OD034286
6 · The paper itself

Abstract

Purpose: Myocardial infarction (MI) with subsequent inflammation is one of the most common heart conditions leading to progressive tissue damage. A reliable imaging marker to assess tissue viability after MI would help determine the risks and benefits of any intervention. In this study, we investigate whether a new mitochondria-targeted imaging agent, Procedure: To test whether the myocardial [ Results: The difference in %ID/cc for Conclusions: Our preliminary preclinical data show that [

Indexed as

[18F]F-AraG[18F]FDGcardiac metabolisminflammationmyocardial infarctionT cell infiltration

Identifiers

PMID38746162
PMCPMC11092840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.